Introduction
============

Ovarian cancer is regarded as the most lethal gynecologic malignancy and a serious threat to womens health worldwide ([@b1-ol-0-0-6432]). The treatment for ovarian cancer patients at an early stage (stages I or II) is effective, with 5-year survival of up to 90%. However, cases diagnosed at an end-stage are approximately 70% (stages III or IV) with survive for 5 years of ≤30% ([@b2-ol-0-0-6432]). The lacks of effective screening strategies for early detection contribute to the delay in diagnosis and the high mortality rate of ovarian carcinogenesis. Thus, deeper research and better understanding of the mechanisms of ovarian cancer will facilitate the identification of reliable diagnostic markers and the development of effective treatment.

Tripartite motif-containing (TRIM)11 is a kind of TRIM protein. TRIM proteins have a tripartite motif consisting of gRING-finger, B-Box and coiled-coil domains ([@b3-ol-0-0-6432]). TRIM11 is identified as an E3 ubiquitin ligase in humans ([@b4-ol-0-0-6432]), PHOX2B (paired-like homeobox 2b) ([@b5-ol-0-0-6432]) and PAX6 (paired-box gene 6) ([@b6-ol-0-0-6432]), thus participate in the development of the nervous system. Moreover, TRIM11 interacts with and destabilizes ARC105, which suppresses ARC105-mediated transcriptional activation ([@b7-ol-0-0-6432]). Recently, it has been reported that TRIM11 is upregulated and play an oncogenic function in glioma ([@b8-ol-0-0-6432]), lung cancer ([@b9-ol-0-0-6432]) and colon cancer ([@b10-ol-0-0-6432]). Several members of TRIM proteins, including TRIM25 ([@b11-ol-0-0-6432]), TRIM27 ([@b12-ol-0-0-6432]) and TRIM29 ([@b13-ol-0-0-6432]), were elevated in ovarian cancer, while TRIM16 expression ([@b14-ol-0-0-6432]) decreased in ovarian cancer. However, the expression, and functions of TRIM11 in ovarian cancer have been insufficiently characterized.

The present study concluded that the level of TRIM11 expression is higher in ovarian cancer tissues than in matched adjacent non-cancerous tissues. We then investigated the biological functions of TRIM11 by knocking down its expression in ovarian cancer cell lines. The TRIM11 knockdown significantly suppressed proliferation and inhibited invasion of cells, and induced apoptosis. Additionally, depletion of TRIM11 inhibited the activities of AKT and ERK. TRIM11 is a potent oncogene in ovarian cancer.

Patients and methods
====================

### Specimen collection and cell culture

A total of 40 patients (median age, 53 years; range, 30--68 years) with ovarian cancer who underwent surgical resection at Clinical Laboratory, the Womens Hospital, Zhejiang University School of Medicine were registered in this project. Ovarian cancer tissues and matched non-cancerous tissues were obtained from the above 40 patients after written informed consent was obtained. Tissue samples were stored in liquid nitrogen at −80°C before used. This study was reviewed and supported by the Ethics Committee of the Womens Hospital, Zhejiang University School of Medicine.

The human ovarian A2780 and SK-OV-3 cell lines were provided by the Cell Bank of the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbeccos modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (both from Gibco, Los Angeles, CA, USA) and 1% penicillin/streptomycin 2 mM L-glutamine. Both cell lines were maintained at 37°C in a 5% CO~2~ incubator.

### RNA extraction and real-time PCR

Total RNA was isolated from tissue samples or cell lines using TRIzol (Invitrogen, Carlsbad, CA, USA) per the manufacturers instructions. After removing the residual DNA with DNase I (Roche Diagnostics, Indianapolis, IN, USA), cDNA was synthesized by reverse transcription of 2 µg of total RNA by using M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific, Inc., Rockford, IL, USA). Real-time PCR was conducted in triplicate on an ABI 7300 machine (Applied Biosystems, Foster City, CA, USA) with SYBR® Green PCR Master mix (Thermo Fisher Scientific, Inc.). GAPDH served as an internal control. The sequences of PCR primers are as follows: TRIM11, 5-CACC TAAGCTGCACAGTTCC-3 and 5-GGCTGCCTCCTAAT TCTTCC-3; GAPDH, 5-CACCCACTCCTCCACCTTTG-3 and 5-CCACCACCCTGTTGCTGTAG-3.

### Western blot analysis

Using RIPA lysis buffer, protein can be extracted from cell lines (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.5% Nonidet P-40) with fresh-added protease inhibitor cocktail (Roche Diagnostics). Protein concentrations depend on Bradford assay. Then equal number of proteins was separated for each sample by SDS-PAGE and blotted onto nitrocellulose filter membranes (EMD Millipore, Bedford, MA, USA). The membranes were incubated in 5% skim milk for 30 min, at room temperature, after that, with primary antibodies at 4°C overnight. Rabbit polyclonal TRIM11 antibody (dilution, 1:500; cat. no. ab111694), rabbit polyclonal MMP-9 antibody (dilution, 1:500; cat. no. ab73734); rabbit polyclonal MMP-2 antibody (dilution, 1:500; cat. no. ab37150); rabbit monoclonal Bcl-2 antibody (dilution, 1:500; cat. no. ab32124); rabbit monoclonal Bax antibody (dilution, 1:500; cat. no. ab32503); rabbit polyclonal Akt antibody (dilution, 1:500; cat. no. ab8805) and rabbit monoclonal pAkt antibody (dilution, 1:500; cat. no. ab81283); rabbit polyclonal ERK antibody (dilution, 1:500; cat. no. ab196883) and rabbit polyclonal p-ERK antibody (dilution, 1:500; cat. no. ab192591) and rabbit polyclonal GAPDH antiboody (dilution, 1:500; cat. no. ab37168) were all purchased from Abcam (Cambridge, MA, USA). Subsequently, the membranes were applied with secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721; Abcam) and detected with the enhanced chemiluminescence system (Bio-Rad, Richmond, CA, USA). GAPDH was used as loading control. Band intensities were assessed on ImageJ software version 1.6 (<http://rsb.info.nih.gov/ij/>; National Institutes of Health, Bethesda, MD, USA).

### RNA interference

TRIM11 small interfering RNA (siRNA) (siTRIM11, 5-CUAUUCAUCUUUCCCGAGA-3) and negative control siRNA (siNC) were from GenePharma (Shanghai, China). A2780 and SK-OV-3 cells were transfected with siRNA or siNC by using Lipofectamine 2000 (Invitrogen) following the manufacturers instructions. At 48 h post-transfection, by real-time PCR and western blot analysis, the knockdown efficiency was assessed.

### Cell proliferation assay

The evaluation of cell proliferation was made by using Cell Counting Kit-8 (CCK-8; Beyotime, Haimen, China) following the manufacturers instructions. A2780 and SK-OV-3 cells were seeded onto 96-well plates (2,000 cells/well) and transfected with siTRIM11 or siNC. After incubation for 0, 24, 48 and 72 h, CCK-8 reagent was added and incubated at 37°C for 1 h. At 450 nm, the absorbance was measured on a microplate reader (Perlong, Beijing, China) with a reference wave length at 655 nm.

### Cell apoptosis analysis

The proportion of apoptotic cells were determined by using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) following the manufacturers instructions. Cells cultured in 6-well plates were transfected with siTRIM11 or siNC. After incubating for 48 h, cells were harvested, labeled with Annexin V-FITC and PI, and analyzed using a FACScan flow cytometry (BD Biosciences, San Jose, CA, USA) within 1 h.

### Transwell invasion assays

The Transwell assay of cell invasion was with 8-µm-pore filters pre-coated with Matrigel (Corning, New York, NY, USA). Cells were treated with siTRIM11 or siNC. At 24 h after treatment, cells were collected and plated in the upper chamber (5×10^4^ cells/well) with DMEM medium. The lower chamber contained DMEM supplemented with 10% FBS. At 22 h, the non-migrating cells were removed, and the filters fixed in 10% formalin, stained by 0.5% crystal violet. Using an inverted microscope, cells in 5-random fields were counted.

### Statistical analysis

Statistical analysis were carried out by GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). All values are presented as the mean ± standard deviation. One-way analysis of variance was used to test the statistical differences. A value of P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Upregulation of TRIM11 in ovarian cancer tissues

Real-time PCR analysis was performed in 40 pairs of ovarian cancer and adjacent non-tumorous tissues and the log2 tumor/normal ratio of each cancer specimen was calculated. As shown in [Fig. 1](#f1-ol-0-0-6432){ref-type="fig"}, overexpression of TRIM11 was found in 77.5% (31/40) of the tested ovarian cancer tissues.

### Knockdown of TRIM11 expression by siRNA transfection

To investigate the biological functions of TRIM11 in ovarian cancer progression, siRNA transfection was used to knock down TRIM11 expression in A2780 and SK-OV-3 cells. As shown in [Fig. 2A](#f2-ol-0-0-6432){ref-type="fig"}, siNC did not change the mRNA expression of TRIM11 compared to wild-type cells. TRIM11 siRNA (siTRIM11) significantly reduced TRIM11 mRNA expression compared to cells transfected with siNC in both cell lines. Western blot analysis revealed that siTRIM11 efficiently inhibited the protein expression of TRIM11 ([Fig. 2B](#f2-ol-0-0-6432){ref-type="fig"}).

### Downregulation of TRIM11 expression inhibits ovarian cancer cell proliferation

To explore whether TRIM11 plays a role in the growth of ovarian cancer cells, CCK-8 assay was performed after siRNA transfection. The proliferation of A2780 and SK-OV-3 cells was remarkably repressed at 24, 48 and 72 h after siTRIM11 transfection ([Fig. 3](#f3-ol-0-0-6432){ref-type="fig"}). These results indicated the inhibitory role of TRIM11-siRNA in the proliferation of ovarian cancer cells.

### Knockdown of TRIM11 induces ovarian cancer cell apoptosis

Determining whether TRIM11 affects apoptosis of ovarian cancer cells, percentages of apoptotic cells were assessed in TRIM11 knockdown cells by Annexin V-FITC/PI staining assay. From flow cytometry analysis, it can be seen that compared with corresponding control cells (siNC), knockdown of TRIM11 in A2780 cells ([Fig. 4A](#f4-ol-0-0-6432){ref-type="fig"}) markedly reduced cell apoptosis. Similar results were received in SK-OV-3 cells ([Fig. 4B](#f4-ol-0-0-6432){ref-type="fig"}).

### Depletion of TRIM11 inhibits ovarian cancer cell invasion

Using a Matrigel-coated Transwell, we evaluated the changes in ovarian cancer cell invasion after TRIM11 siRNA transfection. As shown in [Fig. 5](#f5-ol-0-0-6432){ref-type="fig"}, depletion of TRIM11 in A2780 and SK-OV-3 cells led to markedly reduced cell apoptosis of invasion. These data revealed that TRIM11-siRNA play an inhibitory role on ovarian cancer cell invasion.

### Effects of TRIM11 knockdown on the expression of apoptosis and invasion related proteins

The protein levels of cell apoptosis and invasion related proteins by western blot analysis ([Fig. 6A](#f6-ol-0-0-6432){ref-type="fig"}) were evaluated. The levels of protein of Bcl-2, MMP-2 and MMP-9 were markedly suppressed in A2780 and SK-OV-3 cells with TRIM11 knockdown, but Bax was remarkably increased in TRIM11 knockdown cells.

### Knockdown of TRIM11 suppresses the activity of AKT and ERK in ovarian cancer cells

The effects of TRIM11 on AKT and ERK signaling have been studied in glioma cells ([@b8-ol-0-0-6432]) and lung cancer cells ([@b9-ol-0-0-6432]). [Fig. 6B](#f6-ol-0-0-6432){ref-type="fig"}, shows that transfection of TRIM11 siRNA in ovarian cancer cells obviously suppressed the phosphorylation of AKT and ERK, but does not show any effects on the levels of AKT and ERK expression.

Discussion
==========

Dysregulated expression of several members of TRIM proteins has been found in ovarian cancer tissues ([@b11-ol-0-0-6432]--[@b14-ol-0-0-6432]). The diagnostic and prognostic values of TRIM11 have been reported in gliomas ([@b8-ol-0-0-6432]), lung cancer ([@b9-ol-0-0-6432]) and colon cancer ([@b10-ol-0-0-6432]). Here, we reported that TRIM11 mRNA was efficient in ovarian cancer tissues ([Fig. 1](#f1-ol-0-0-6432){ref-type="fig"}). Next, we studied the functions of TRIM11 in ovarian cancer by knockdown its expression with specific siRNA. Reduced expression of TRIM11 significantly suppressed proliferation of cells ([Fig. 3](#f3-ol-0-0-6432){ref-type="fig"}) and invasion ([Fig. 5](#f5-ol-0-0-6432){ref-type="fig"}), and induced apoptosis ([Fig. 4](#f4-ol-0-0-6432){ref-type="fig"}). These data were consistent with previous investigation in other types of human cancer cells ([@b8-ol-0-0-6432]--[@b10-ol-0-0-6432]). The present study together with the previous findings suggested the important role of TRIM11 in cancer biology.

Members of Bcl-2 family are critical mediators for cell apoptosis promoting cell survival (e.g., Bcl-2 and Bcl-xL) and initiation of apoptosis (e.g., Bax and Bak) ([@b15-ol-0-0-6432]). Members of MMP family degrade extracellular matrix and cell surface proteins, thus playing an important role in cancer cell invasion ([@b16-ol-0-0-6432]). High levels of MMP-2 and MMP-9 predict poor survival in patients at advanced-stage of ovarian cancer ([@b17-ol-0-0-6432]). The activation of AKT and ERK pathways is involved in the regulation of Bcl-2 family ([@b18-ol-0-0-6432],[@b19-ol-0-0-6432]) and MMP family proteins ([@b20-ol-0-0-6432],[@b21-ol-0-0-6432]). Selective targeting of AKT or ERK pathways may block cancer progression ([@b22-ol-0-0-6432]--[@b24-ol-0-0-6432]). The effects of TRIM11 on AKT and ERK signaling have been studied in gliomas ([@b8-ol-0-0-6432]) and lung cancer cells ([@b9-ol-0-0-6432]). In the present study, we showed that knockdown of TRIM11 reduced phosphorylated levels of AKT and ERK, and the protein levels of Bcl-2, MMP-2 and MMP-9, whereas increased the protein levels of Bax in ovarian cancer cells ([Fig. 6](#f6-ol-0-0-6432){ref-type="fig"}), suggesting that in ovarian cancer cells, targeting TRIM11 could be a successful anticancer strategy.

In conclusion, the expression of TRIM11 in ovarian cancer tissues was remarkably increased compared to normal adjacent tissues. The proliferation and invasion of ovarian cancer cells can be suppressed in ovarian cancer cells by depleting of TRIM11. We also illustrated that TRIM11 plays a key role and perform the functions by adjusting the levels of AKT and ERK.

![TRIM11 mRNA expression in ovarian cancer tissues. TRIM11 mRNA levels in ovarian cancer and matched normal tissues from 40 patients were determined by real-time PCR, with GAPDH as a control. The y-axis is log2 (tumor/normal) value. Positive log2 value indicated increased upregulation of TRIM11 in cancer tissues while negative log2 indicated downregulation of TRIM11 in cancer tissues. TRIM11, tripartite motif-containing 11.](ol-14-02-2125-g00){#f1-ol-0-0-6432}

![TRIM11 expression was repressed by specific siRNA transfection. A2780 and SK-OV-3 cells were transfected with siNC or TRIM11 siRNA (siTRIM11). (A) At 48 h after transfection, TRIM11 mRNA levels were determined by real-time PCR analysis. (B) TRIM11 protein levels were determined by western blot analysis with GAPDH as a loading control. Three independent experiments were performed for quantification (mean ± standard deviation) (lower panel). \*\*\*P\<0.001 vs. siNC. TRIM11, tripartite motif-containing 11; siRNA, small interfering RNA; siNC, negative control siRNA-transfected cells; siTRIM11, TRIM11 siRNA-transfected cells; WT, wild-type cells.](ol-14-02-2125-g01){#f2-ol-0-0-6432}

![Knockdown of TRIM11 reduced ovarian cancer cell proliferation. (A) A2780 and (B) SK-OV-3 cells were transfected with siTRIM11 or siNC. Cell proliferation was detected by CCK-8 assay at 0, 24, 48 and 72 h after transfection. \*\*\*P\<0.001 vs. siNC. TRIM11, tripartite motif-containing 11; siTRIM11, TRIM11 siRNA-transfected cells; siNC, negative control small interfering RNA-transfected cells; CCK-8, Cell Counting Kit-8; WT, wild-type cells.](ol-14-02-2125-g02){#f3-ol-0-0-6432}

![Suppressing TRIM11 expression induces ovarian cancer cell apoptosis. (A) A2780 and (B) SK-OV-3 cells were transfected with indicated siRNA. After 48-h of culture, cells were collected, stained with Annexin V/PI and analyzed by flow cytometry. Three independent experiments were performed for quantification (mean ± standard deviation). \*\*\*P\<0.001 vs. siNC. TRIM11, tripartite motif-containing 11; siRNA, small interfering RNA; PI, propidium iodide; siNC, negative control siRNA-transfected cells; WT, wild-type cells; siTRIM11, TRIM11 siRNA-transfected cells.](ol-14-02-2125-g03){#f4-ol-0-0-6432}

![Knockdown of TRIM11 inhibits ovarian cancer cell invasion. Transwell invasion assay was performed in (A) A2780 and (B) SK-OV-3 cells. Three independent experiments were performed for quantification (mean ± standard deviation). \*\*\*P\<0.001 vs. siNC. TRIM11, tripartite motif-containing 11; siNC, negative control small interfering RNA-transfected cells; WT, wild-type cells; siTRIM11, TRIM11 siRNA-transfected cells.](ol-14-02-2125-g04){#f5-ol-0-0-6432}

![Effects of TRIM11 knockdown on the protein expression of (A) apoptosis and invasion-related regulators, and (B) the activation of AKT and ERK in ovarian cancer cells. Western blot analysis was performed with GAPDH as a loading control. Three independent experiments were performed for quantification (mean ± standard deviation) (right panel). \*\*P\<0.01 and \*\*\*P\<0.001 vs. siNC. TRIM11, tripartite motif-containing 11; WT, wild-type cells; siNC, negative control small interfering RNA-transfected cells; siTRIM11, TRIM11 siRNA-transfected cells.](ol-14-02-2125-g05){#f6-ol-0-0-6432}
